APPS 0  |  CONTACT US  |  CAREERS  |  LOCATE US  |  DOWNLOADS  |  BLOG
CONNECT WITH US ON
Financial Services | Broking & Distribution | Institutional Equities | Private Wealth Management | Investment Banking | Private Equity | Asset Management | Commodities | Home Finance
Broking & Distribution > Markets > Company Information > News

Aurobindo Pharma Ltd

BSE Code : 524804   |   NSE Symbol : AUROPHARMA   |   ISIN : INE406A01037
OVERVIEW INFORMATION FINANCIALS COMPANY NEWS CORPORATE ACTIONS
 
Aurobindo Pharma to hold board meeting   21-Jul-2014 | 15:55
Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 07 August 2014, to consider, the Un-Audited Financial Results of the Company for the quarter ended 30 June 2014 (Q1).Powered by Capital Market - Live News...
Aurobindo Pharma to hold AGM   03-Jun-2014 | 15:26
Aurobindo Pharma will hold the 27th Annual General Meeting (AGM) of the Company on 27 August 2014. Powered by Capital Market - Live News...
Aurobindo Pharma fixes record date for 2nd interim dividend   03-Jun-2014 | 15:24
Aurobindo Pharma has fixed 12 June 2014 as the record date for the purpose of payment of second interim dividend for the year 2013-14.The interim dividend will be paid on or before 25 June 2014.Powered by Capital Market - Live News...
Aurobindo Pharma gets USFDA approval for Divalproex Sodium tablets   03-Jun-2014 | 14:37
Aurobindo Pharma announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Extended-release Tablets USP 250mg and 500mg (ANDA 202419). The product is ready for launch. Divalproex Sodium Extended-release Tablets USP 250mg and 500mg is the generic equivalent ofAbbVie Inc's Depakote® ER Extended-release Tablets,...
Aurobindo Pharma to hold board meeting   19-May-2014 | 10:27
Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2014 to consider and approve the Audited Financial Results of the Company for the financial year ended 31 March 2014, to consider recommendation of Final Dividend, if any, for the year 2013-14, and to consider the proposal of payment of Second Interim Dividend for the year 2013-14.Powered by Capita...
Aurobindo Pharma gets Court approval for scheme of arrangement  12-May-2014 | 11:03
Aurobindo Pharma announced that the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad has sanctioned the Scheme of Arrangement between Aurobindo Pharma and Curepro Parenterals and their respective shareholders and creditors (Scheme) under Sections 391 to 394 of the Companies Act, 1956. The Scheme provides for transfer of injectables Unit IV of Aurobindo to Curepro, its wholly-owne...
  Company Information :   Company List A-Z  |   Snapshot  |   Volume Chart  |   Investor Returns  |   Score Board  |   Company Peer Comparison  |   Background  |   Board of Directors  |   Quarterly Results  |   Balance Sheet  |   Share Holding Pattern  |   MF Holdings  |   Profit & Loss  |   Key Ratios / Cash Flow  |   Company News  |   Bonus / Split / Rights  |   Dividend / Book Closure  |   Capital Structure  |   Insider Trading History  |   Top Companies By MCAP  |   Top Dividend Yield  
  Equity Market       Derivatives       Mutual Funds       Commodities       Currencies       News       IPO    
Login
Login Open An Account Trade Now
50% Cash Back
Open an account
Name :
Mobile :
Email :
State :
City :
Interested in
*Terms & Conditions
Financial Services Products & ServicesBusiness PartnerMarket InfoResearchQuick LinksBusinesses
Stocks   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Mutual Funds   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Disclaimer | Additional Disclaimer for U.S. Persons  | Feedback | Locate Us | Do Not Call Form
Motilal Oswal Securities Ltd. (MOSL) Member of NSE, BSE and MCX-SX
Regd Office: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; CIN no.: U65990MH1994PLC079418; Tel No.: 022 3980 4263

Customer having any query / feedback / clarification may write to query@motilaloswal.com
In case of grievances for Securities Broking write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com, for Commodity Broking to commoditygrievances@motilaloswal.com

Registration Nos: NSE(Cash) INB231041238; NSE(F&O): INF231041238; NSE(CD): INE231041238; BSE(Cash): INB011041257; BSE(F&O) INF011041257; BSE(CD); MCX-SX (Cash) : INB261041231; MCX-SX (F&O): INF261041231; MCX-SX (CD): INE261041231; CDSL: IN-DP-CDSL-09-99; NSDL: IN-DP-NSDL-152-2000; AMFI:ARN 17397. PMS: INP000000670; PMS & Mutual Funds are offered through Motilal Oswal Asset Management Company Ltd(MOAMC) which is group company of MOSL. PMS (Regn No. INP000004409) is offered through Motilal Oswal Wealth Management Ltd. (MOWML) which is a group company of MOSL. Motilal Oswal Commodities Broker Pvt Ltd. (MOCBPL) member of MCX, NCDEX and NCDEX Spot. MCX Member ID 29500, NCDEX-NCEDX-CO-04-00114, NCDEX Spot Exchange Limited 10014. FMC Unique membership code: MCX: MCX/TCM/CORP/0725, NCDEX: NCDEX/TCM/CORP/0033, Commodity Services are offered through MOCBPL which a group company of Motilal Oswal Securities Ltd. Motilal Oswal Securities Ltd is a distributor of Mutual Fund & IPOs. Investment in Securities is subject to market risk.

Motilal Oswal Securities International Pvt Limited CRD-164319 SEC - 08-69093
Copyright © 2014 MOSL. All Rights Reserved. Market Data provided by C-MOTS Infotech (ISO 9001:2008 Certified)

Site best viewed in IE 7.0+, Mozila Firefox 3.0+ and Google Chrome at 1024 x 768 pixels resolution
GET QUOTES    RESEARCH REPORT  
Our research reports can be searched based on companies covered (COM), sectors covered (SEC) or report names (RPT). Type any three characters of your query to see a search list.